35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

T.M Kim,S-H Lee,G-C Chang,J-Y Shih,M.J Hochmair,J.K Sabari,A.I Spira,C.A Schioppa,J.B Rose,M Chioda,A Panaccione,P Mahadevia,B.C Cho

doi:10.1016/j.annonc.2022.02.044

35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

T.M Kim, S-H Lee + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2022.02.044

Copy DOI

Journal: Annals of Oncology	Publication Date: Apr 1, 2022
Citations: 2	License type: elsevier-specific: oa user license

Affiliation: Yonsei University, Chung Shan Medical University Hospital, Janssen (United States), National Taiwan University Hospital, Seoul National University Hospital, Samsung Medical Center

#Advanced Non-small Cell Lung Cancer #Epidermal Growth Factor Receptor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, is approved for the treatment of patients with advanced EGFR ex20ins NSCLC that progressed on or after platinum-based chemotherapy. We present initial real-world experience with amivantamab acquired through the global PAA program.

Full Text